September 2014
MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, pA8
Product Review
The article offers information about the Zontivity protease-activated receptor-1 (PAR-1) antagonist from Merck & Co. Inc.


Related Articles

  • NEW PRODUCTS.  // Monthly Prescribing Reference;Aug2014, Vol. 30 Issue 8, pA10 

    The article offers brief information on two drugs including the Entyvio from the firm Takeda Pharmaceuticals and the Zontivity from the firm Merck & Co.

  • Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p282 

    The article presents the results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) study led by North Carolina's Duke Clinical Research Institute (DCRI). The study is the first clinical trial of vorapaxar from Merck & Co. Inc. for the prevention...

  • Xenon Snags Another Cardiovascular Deal.  // Bioworld Week;6/15/2009, Vol. 17 Issue 24, p4 

    The article reports on the deal offered by Merck & Co. Inc. to a company based in Vancouver, British Columbia. It states that Xenon Pharmaceuticals Inc. received the deal from Merck in exchange for the development of a cardiovascular agent. According to the article, Xenon will receive funding...

  • Huge fight expected when statin patents expire. Moyer, Paula // Drug Topics;8/8/2005 Supplement, p24s 

    This article discusses the potential conflict over generic formulation plans for statin in the United States. A generic formulation for simvastatin has received temporary approval and others are expected to follow. However, major drug companies that manufacture statins, such as Pfizer Inc. and...

  • Feds Order Merck to Submit Marketing Information.  // MondayMorning;11/14/2011, Vol. 19 Issue 41, p3 

    The article presents requests from U.S. government investigators for Merck & Co. to submit information about the marketing of heart and anti-infective drugs. It notes that the U.S. Justice Department issued a subpoena asking for information about the marketing and selling activities for the...

  • HEALTH. Watson, Noshua // Fortune;12/9/2002, Vol. 146 Issue 12, p40 

    Reports that C-reactive protein (CRP) is the best indicator of a heart attack. Discussion of which drug companies produce statins, such as Pfizer and Merck; Statement that test makers like Dade Behring and Beckman will benefit from all the people seeking a CRP screen; Mention of aspirin as...

  • Molecule of the Month. Lindsley, Craig W. // Current Topics in Medicinal Chemistry;Mar2008, Vol. 8 Issue 5, p434 

    Is Zetia™ a A ‘Do Nothing’ Drug? After months of delays and on the eve of meetings with congressional investigators, results from the much anticpated ENHANCE clinical trial for Vytorin™ were finally disclosed (January 15, 2008) to the dismay of pharmacuetical giants...

  • Is the U.S. ready for a third class of drugs? Levy, Sandra // Drug Topics;2/7/2005, Vol. 149 Issue 3, p74 

    The possible development and emergence of third class of drugs in the U.S. resulted to varying opinions and discussions among pharmacists and pharmacy trade associations stressing that a third class of drugs would allow patients to buy a drug without prescription, but only after speaking with a...

  • Cardiology. Bastian, Alex // Medical Marketing & Media;Dec2013, Vol. 48 Issue 12, p39 

    The article provides information on several cardiologic drugs including Alirocumab for hypercholesterolemia and hyperlipoproteinemia from Sanofi-Aventis SA/Regeneron, Anacetrapib for atherosclerosis from Merck & Co. Inc. and Evolocumab for hypercholesterolemia, hyperlipoproteinemia from Amgen Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics